Results 171 to 180 of about 8,174 (197)

Daclatasvir

Reactions Weekly, 2017
openaire   +1 more source

Asunaprevir/daclatasvir

Reactions Weekly, 2019
openaire   +1 more source

Daclatasvir/sofosbuvir

Reactions Weekly, 2020
openaire   +2 more sources

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

New England Journal of Medicine, 2014
Mark S Sulkowski, K Rajender Reddy, Eric Lawitz   +2 more
exaly  

Daclatasvir/sofosbuvir

Reactions Weekly, 2019
openaire   +2 more sources

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

Lancet, The, 2014
Michael Manns, Stanislas Pol, Cheng-Yuan Peng   +2 more
exaly  

Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial

Journal of Antimicrobial Chemotherapy, 2020
Anahita Sadeghi, Ali Ali Asgari, Mahnaz Montazeri   +2 more
exaly  

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

Hepatology, 2015
Eric Lawitz, Paul J Pockros, Paul J Thuluvath   +2 more
exaly  

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

Gut, 2016
Kerstin Herzer, Peter Ferenci, Michael Gschwantler   +2 more
exaly  

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

Hepatology, 2014
Yoshiyasu Karino, Koichi Takaguchi, Namiki Izumi   +2 more
exaly